Clinical data | |
---|---|
Trade names | Esmeron, Zemuron |
Other names | [3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enyl-2,3,4,5-tetrahydropyrrol-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate |
AHFS/Drugs.com | Monograph |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | NA |
Protein binding | ~30% |
Metabolism | some de-acetylation |
Elimination half-life | 66–80 minutes |
Excretion | Unchanged, in bile and urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.122.235 |
Chemical and physical data | |
Formula | C32H53BrN2O4 |
Molar mass | 609.690 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Rocuronium bromide (brand names Zemuron, Esmeron) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia to facilitate tracheal intubation by providing skeletal muscle relaxation, most commonly required for surgery or mechanical ventilation. It is used for standard endotracheal intubation, as well as for rapid sequence induction (RSI).[2]